Evidence map›Paper›PMID 27934662›Full record

ArticleBiology open2017

Cardiomyocyte--specific expression of the nuclear matrix protein, CIZ1, stimulates production of mono-nucleated cells with an extended window of proliferation in the postnatal mouse heart.

Sumia A Bageghni, Georgia A Frentzou, Mark J Drinkhill, William Mansfield, Dawn Coverley, Justin F X Ainscough

Open access · goldAbstract read
In one paragraph

Article in Biology open, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Sumia A BageghniLICAMM, University of Leeds, Leeds LS2 9JT, UK.
Georgia A FrentzouLICAMM, University of Leeds, Leeds LS2 9JT, UK.
Mark J DrinkhillLICAMM, University of Leeds, Leeds LS2 9JT, UK.
William MansfieldStem Cell Institute, University of Cambridge, Cambridge CB2 1QR, UK.
Dawn CoverleyBiology Department, University of York, York YO10 5DD, UK.
Justin F X AinscoughLICAMM, University of Leeds, Leeds LS2 9JT, UK justin.ainscough@york.ac.uk.ORCID http://orcid.org/0000-0003-0231-433X
University of Leeds · GBUniversity of York · GBWellcome/MRC Cambridge Stem Cell Institute · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myocardial injury in mammals leads to heart failure through pathological cardiac remodelling that includes hypertrophy, fibrosis and ventricular dilatation. Central to this is inability of the mammalian cardiomyocyte to self-renew due to entering a quiescent state after birth. Modulation of the cardiomyocyte cell-cycle after injury is therefore a target mechanism to limit damage and potentiate repair and regeneration. Here, we show that cardiomyocyte-specific over-expression of the nuclear-matrix--associated DNA replication protein, CIZ1, extends their window of proliferation during cardiac development, delaying onset of terminal differentiation without compromising function. CIZ1-expressing hearts are enlarged, but the cardiomyocytes are smaller with an overall increase in number, correlating with increased DNA replication after birth and retention of an increased proportion of mono-nucleated cardiomyocytes into adulthood. Furthermore, these CIZ1 induced changes in the heart reduce the impact of myocardial injury, identifying CIZ1 as a putative therapeutic target for cardiac repair.

Indexed as

Cardiac functionCardiomyocyteCIZ1DNA replicationNuclear-matrix protein

Identifiers

PMID27934662
PMCPMC5278428
OpenAlexW2559425467

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.